• Photocure reported publication of a peer-reviewed study modeling recurrence and progression risk in non-muscle invasive bladder cancer patients undergoing blue light cystoscopy.
• Study results were previously presented as an abstract at the 2025 AUA Congress.
• Models built from a U.S. patient registry aim to improve individualized risk prediction under current treatment practices.
• Findings indicate tumor characteristics raise recurrence and progression risk, while adjuvant BCG treatment lowers progression risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Photocure ASA published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.